Physician

Charles M Farber, M.D, PHD

According to 2025 Medicare claims, Charles Farber, M.D, PHD (NPI: 1144218215) practices medical oncology in the Newark, NJ market, with the plurality of this provider's patient population coming from Morris, NJ. This provider's primary affiliated billing organization is PRACTICE ASSOCIATES MEDICAL GROUP (NPI: 1427016385; TIN: 202088165) and primary practice location at 07960-6136. Farber is affiliated with the Atlantic ACO (ACO ID: A1026), participating under the MSSP model.

Farber's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 448 traditional Medicare patients, billed 3,056 HCPCS/CPT codes, and received $191,562 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 173 prescription claims across 52 beneficiaries totaling $463,914 in drug costs, led by Jakafi (Ruxolitinib Phosphate). 2021 DME data shows 12 claims. Open Payments data shows 384 records totaling $1,025,037. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a higher plateau to a lower plateau, from $1,127,654 to $191,562. Similarly, Part D prescription costs have fallen sharply in recent years, from $1,379,083 to $463,914. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $6,242 to $467.